Sergey V. Veretennikov and Michael J. Campbell, MD

Slides:



Advertisements
Similar presentations
Diabetes, Anemia and Chronic Kidney Disease Josephine Carlos-Raboca,M.D., F.P.S.E.M., Endocrinology, Diabetes and Metabolism Makati Medical Center.
Advertisements

Uncontrolled secondary hyperparathyroidism in a haemodialysis patient Jordi Bover, MD, PhD Fundació Puigvert Barcelona, Spain © Springer Healthcare, a.
Anemia an enigma in chronic kidney disease Mohammad Asgar Khan, MD.
 Serum Levels of Phosphorus, Parathyroid Hormone, and Calcium and Risks of Death and Cardiovascular Disease in Individuals With Chronic Kidney Disease:
Hyperparathyroidism in Chronic Kidney Disease 醫五 李政霆.
Nephrology Grand Rounds 5/13/08. Refractory Hyperparathyroidism Brad Weaver.
PARATHYROID HORMONE, HYPERPARATHYROIDISM CKD, & PTH ASSAYS David Plaut & Shanti Narayanan Summer, 2012.
Hyperparathyroidism.
Prevalance of Chronic Kidney Disease 26 million people have diagnosed chronic kidney 26 million people have diagnosed chronic kidney disease (CKD) ( National.
The National Kidney Foundation’s Kidney Early Evaluation Program TM “The Greater New York Experience” Ellen H. Yoshiuchi, MPS Division Program Director.
CKD Dr;BASHARDOOST. CKD –SOME DEFINITIONS IRREVERSIBLE LOSS OF GFR CKD results when a disease process damages the structural or functional integrity of.
Chapter 37 Chronic Kidney Disease: The New Epidemic
Anemia in Hemodialysis 1. 2 Etiology The anemia of chronic kidney disease (CKD) is primarily due to insufficient production of the glycoprotein hormone.
Secondary Hyperparathyroidism in CKD: Usefulness of VDR Agonists Reference: Sprague SM, Coyne D. Control of secondary hyperparathyroidism by vitamin d.
به نام دوست. C ASE PRESENTATION Dr.Pardis Nematollahi By : Amir vard.
Vitamin D deficiency and anemia in early chronic kidney disease 2010/05/18 R4 이완수 2010.
Date of download: 6/22/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Surgical Treatment of Hyperparathyroidism in Patients.
CKD Treatment 순천향 대학교병원 신장내과 R3 김재연. Chronic kidney disease (CKD) encompasses a spectrum of different pathophysiologic processes associated with abnormal.
Volume 68, Pages S24-S28 (July 2005)
Medical Directorate, National Kidney Foundation, Singapore
Commentary on ‘The DOPPS Practice Monitor for US Dialysis Care: Potential Impact of Recent Guidelines and Regulatory Changes on Management of Mineral.
Evaluating the Effectiveness of Social Work Interventions:
2016 Annual Data Report, Vol 1, CKD, Ch 8
Endocrine Disorders Parathyroid Gland
Chronic Kidney disease
M.A.C. Manoukian; J.A. Harris; A.D. Carr M.D.; M.J. Campbell M.D.
Golden Rules to Keep Kidneys Healthy
Claudia Beals, MD John Detesco Erdal Sarac, MD FACP FASN
Department of Nephrology- Ain Shams University, Cairo, Egypt
The ECHO Observational Study
CARDIOVASCULAR CORELATIONS IN CHILDREN WITH END STAGE RENAL DISEASE
Introduction CKD-MBD. Introduction CKD-MBD Regulation of PTH Secretion.
Volume 67, Pages S1-S7 (June 2005)
High Prevalence of Vitamin D Inadequacy and Implications for Health
Acute and Chronic Renal Failure
Advancing Management of Anemia With the Latest Data From ERA-EDTA 2018
Bone Imaging and Chronic Kidney Disease: Will High-Resolution Peripheral Tomography Improve Bone Evaluation and Therapeutic Management?  Justine Bacchetta,
Objectives Early initiation of continuous renal replacement therapy
Furosemide-Induced Severe Hypocalcemia in Latent Hypoparathyroidism
Fibroblast Growth Factor 23 and CKD Prognosis
American Journal of Kidney Diseases 
Mitchell H. Rosner, W. Kline Bolton  Kidney International 
Spectrum and Burden of Erythropoiesis-Stimulating Agent Hyporesponsiveness Among Contemporary Hemodialysis Patients  Jiacong Luo, MD, MS, MPH, Donna E.
Douglas S. Fuller, MS, Ronald L. Pisoni, PhD, MS, Brian A
H. Clark Hoagland, M.D.  Mayo Clinic Proceedings 
High Prevalence of Vitamin D Inadequacy and Implications for Health
Dialysis Facility Ownership and Epoetin Dosing in Hemodialysis Patients: A Dialysis Provider’s Perspective  J. Michael Lazarus, MD, Raymond M. Hakim,
Volume 79, Pages S24-S27 (April 2011)
M. Fukagawa, S. Nakanishi, J.J. Kazama  Kidney International 
Chapter 3: Management of progression and complications of CKD
Overview of the 2017 KDIGO CKD-MBD Update: Practice Implications for Adult Hemodialysis Patients  Judith Beto, PhD, RDN, FAND, Nisha Bhatt, MD, Teresa.
Yasuhiro Hamada, Masafumi Fukagawa  Kidney International 
Volume 64, Issue 5, Pages (November 2003)
Volume 79, Pages S20-S23 (April 2011)
Clinical relevance of FGF-23 in chronic kidney disease
Volume 67, Pages S33-S36 (June 2005)
Mortality, Hospitalization, and Technique Failure in Daily Home Hemodialysis and Matched Peritoneal Dialysis Patients: A Matched Cohort Study  Eric D.
Plasma Parathyroid Hormone Level and Prevalent Cardiovascular Disease in CKD Stages 3 and 4: An Analysis From the Kidney Early Evaluation Program (KEEP) 
Volume 68, Pages S24-S28 (July 2005)
The DOPPS Practice Monitor for US Dialysis Care: Potential Impact of Recent Guidelines and Regulatory Changes on Management of Mineral and Bone Disorder.
Daniel E. Weiner, MD, MS, Mark J. Sarnak, MD, MS 
Update in Nephrology 2013 Does AKI lead to ESRD?
Commentary on ‘The DOPPS Practice Monitor for US Dialysis Care: Potential Impact of Recent Guidelines and Regulatory Changes on Management of Mineral.
International and Racial Differences in Mineral and Bone Disorder Markers and Treatments Over the First 5 Years of Hemodialysis in the Dialysis Outcomes.
Pediatric in-center hemodialysis patients
Recent developments in the management of secondary hyperparathyroidism
CKD Is a Global Burden With Major Implications
Figure 1. (A) Composite renal outcome, (B) worsening kidney function, and (C) incident albuminuria by fasting glucose ... Figure 1. (A) Composite renal.
Volume 64, Pages S131-S136 (November 2003)
Perioperative considerations for parathyroidectomy in patients on dialysis. Perioperative considerations for parathyroidectomy in patients on dialysis.
Presentation transcript:

Effects of Parathyroidectomy on Anemia in Patients with End-Stage Renal Disease Sergey V. Veretennikov and Michael J. Campbell, MD University of California, Davis Medical Center Section of Endocrine Surgery INTRODUCTION RESULTS CONCLUSIONS Chronic kidney disease (CKD) affects approximately 20 million Americans. Almost 900,000 patients have end-stage renal disease (ESRD). Patients with CKD often suffer from anemia due to poor iron utilization and erythropoietin (EPO) resistance. Patients with CKD frequently develop elevated parathyroid hormone (PTH) levels secondary to decreased conversion of vitamin D to its active form and decreased excretion of phosphate. This is termed secondary hyperparathyroidism High PTH levels may contribute to EPO resistance, resulting in worsening anemia refractory to artificial EPO supplementation. Current treatment options for secondary hyperparathyroidism include the use of calcimimetics (e.g. cinacalcet) or parathyroidectomy. We identified 19 patient who underwent 20 operations and met our inclusion criteria The mean pre-operative PTH was 1142.2 pg/mL. The mean post-operative PTH was 172.35 pg/mL. The mean pre-operative hemoglobin was 11.6 gm/dL. The mean post-operative hemoglobin was 12.3 gm/dL. The mean pre-operative hematocrit is 34.5%. The mean post-operative hematocrit was 37.4 %. Parathyroidectomy is a viable method to reduce PTH levels, especially in those patients with disease refractory to medical therapy. Successful parathyroidectomy does not appear to improve anemia in patients with renal hyperparathyroidism. Larger studies incorporating control patients are needed to better evaluate the effect of parathyroidectomy on patients with ESRD. Limitations Our small sample size limited our statistical power. We have limited follow-up data on our patients which decreased our ability to detect differences in pre-op and post-op Hgb and Hct. We do have information on the dose of EPO pre- and post-operatively at this time. OBJECTIVES REFERENCES The purpose of this study is to evaluate the effect of parathyroidectomy on hemoglobin (Hgb) and hematocrit (Hct) in patients with ESRD. Chow TL, Chan TT, Ho YW, Lam SH. Improvement of anemia after parathyroidectomy in Chinese patients with renal failure undergoing long-term dialysis. Arch Surg. 2007 Jul;142(7):644–8. Rao DS, Shih MS, Mohini R. Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia. N Engl J Med. 1993;328(3):171-175. Nichols P, Owen JP, Ellis HA, Farndon JR, Kelly PJ, Ward MK. Parathyroidectomy in chronic renal failure: a nine-year follow-up study. Q J Med. 1990 Nov;77(283):1175–1193. Chen C, Wu H, Zhong L, Wang X, Xing Z-J, Gao B-H. Impacts of parathyroidectomy on renal anemia and nutritional status of hemodialysis patients with secondary hyperparathyroidism. International Journal of Clinical and Experimental Medicine. 2015;8(6):9830-9838. Bhadada SK, Arya AK, Parthan G, Singh P. The resolution of anemia after curative parathyroidectomy is sustained even after a decade. Indian Journal of Endocrinology and Metabolism. 2015;19(5):691-692. doi:10.4103/2230-8210.163215. MATERIALS AND METHODS Review of all patients with ESRD receiving dialysis who had a parathyroidectomy between January 2005 and December 2015 using the EMR system. Hgb and Hct values measured preoperatively and then 1 month and 6 months after surgery were compared using a students t-test